PD-L1 is regulated by the ubiquitin/proteasome pathway through E3 ligases and deubiquitinating enzymes, suggesting that targeting PD-L1 ubiquitination might reduce tumor immunosuppression [10]. The gene discussed is CD274; the disease is neoplasm.